The acronym for this newly created function turns out to be OOPS. Coincidence or a subliminal apology to all of the stockholders, employees, physicians and patients they screwed over with their ignorance and irresponsibility? Since the second choice would indicate awareness, remorse and cleverness and wit, none of which are in long supply in Bridgewater, I'm going with A.
i'm no wall street analyst, but how is it that this place is still in business? look at these pathetic numbers: KRYSTEXXA net sales increased $2.1 million, or 52%, to $6.1 million for the three-month period ended June 30, 2013. The increase in KRYSTEXXA net sales is substantially due to the impact of price increases for the product. Since the beginning of 2012, the selling price of KRYSTEXXA has increased by approximately 134% from the original list price of $2,300 per vial to the current list price of $5,390 per vial. SALES: 2,058 vials sold for the three months ending June 30, 2013 1,624 vials sold for the three months ending March 31, 2013 1,883 vials sold for the three months ending June 30, 2012 How's that (slam dunk) $88MM forecast that we had coming out of our launch meeting looking now?!?!? 9 quarters in, and they haven't even sold a third of that. You can't make this shit up...
ROFLOL....you are too funny. There is nothing illegal about raising the price per vial. We are never going to make another batch ....as the supply dwindles the price will go up.
It is all quite moot at this point. The people with any options for finding another job have left. All that remains are the dregs who can't or won't leave.
Just working another job and doing reorders. Certainly not selling any of this shit. I can't believe we are still open for business. I do, however, love getting paid for doing close to absolutely nothing, though.
Change in Directors or Principal Officers, Financial Statements and E Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. (e) Savient Pharmaceuticals, Inc. (the "Company") has entered into Incentive Bonus Agreements (the "Incentive Agreements") with each of the Company's three Co-Presidents, Philip K. Yachmetz, John P. Hamill and Richard Crowley and with the Company's Senior Vice President and Chief Medical Officer, Dr. Kenneth M. Bahrt. The Incentive Agreements with each of Mssrs. Yachmetz, Hamill and Crowley were entered into on October 11, 2013 and provide for a one-time incentive payment of $200,000 to each individual. The Incentive Agreement with Mr. Bahrt was entered into on September 11, 2013 and provides for an incentive payment of $180,000, payable in two equal installments. Under the Incentive Agreements, Mssrs. Yachmetz, Hamill, Crowley and Bahrt agree to repay the Company the full amount of the incentive payment if their employment with the Company is terminated, other than due to termination by the Company without "cause," as defined in the Incentive Agreements, before the Company completes a sale or merger of the Company, a sale of all or substantially all of the Company's assets or a debt exchange, recapitalization, refinancing, or restructuring of substantially all of the Company's outstanding indebtedness, or if none of the aforementioned events is completed before April 1, 2014. The foregoing description of the Incentive Agreements does not purport to be complete and is qualified in its entirety by reference to the Form of Incentive Agreement, a copy of which is attached hereto as Exhibit 10.1 and incorporated herein by reference.
unforgivable. these clowns failed to perform and they are paying to keep them around to bury the corpse they killed.